Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Clofazamine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection

Next Previous
Trial Profile

ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Clofazamine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofazimine (Primary)
  • Indications Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ICoN-1
  • Sponsors MannKind Corporation

Most Recent Events

  • 08 May 2025 According to a MannKind Corporation media release, 85% of anticipated sites have been activated in five countries (U.S., Japan, Australia, South Korea, Taiwan) 55 patients randomized in four countries (U.S., Japan, Australia, South Korea). Expect to meet the interim enrollment target of 100 patients by YE 2025.
  • 26 Feb 2025 According to a MannKind Corporation media release, Approximately 70% of anticipated sites have been activated in four countries (U.S., Japan, Australia, South Korea) with Patients randomized in two countries (U.S. and Australia) and company expects to meet the interim enrollment target by YE 2025
  • 07 Nov 2024 According to a MannKind Corporation media release, approximately 230 participants to be randomized at 100+ sites for a minimum of 180 evaluable participants.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top